# OnCo record hutchmed (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/hutchmed/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "hutchmed" ;
  schema:name "Hutchmed"@en ;
  schema:alternateName "HUTCHMED (China)"@en, "Hutchison China MediTech"@en, "Chi-Med"@en, "和黄医药"@en, "Hutchison Medipharma"@en, "HUTCHMED"@en ;
  schema:description "Hutchmed discovered fruquintinib, the first Chinese cancer drug approved by the FDA for a common cancer, and savolitinib, its MET inhibitor partnered with AstraZeneca."@en ;
  schema:url <https://onco.cc/companies/hutchmed/>, <https://www.hutch-med.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.hutch-med.com/> ;
  onco:tag "china" ;
  schema:addressCountry "CN" ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:drugs <https://onco.cc/drugs/fruquintinib/>, <https://onco.cc/drugs/savolitinib/>, <https://onco.cc/drugs/surufatinib/> ;
  onco:companies <https://onco.cc/companies/takeda/>, <https://onco.cc/companies/astrazeneca/> ;
  onco:trials <https://onco.cc/trials/nct06584032/>, <https://onco.cc/trials/nct05009836/>, <https://onco.cc/trials/nct06601504/>, <https://onco.cc/trials/nct06361888/>, <https://onco.cc/trials/nct03091192/>, <https://onco.cc/trials/nct03778229/>, <https://onco.cc/trials/nct07228247/>, <https://onco.cc/trials/nct07396584/> ;
  onco:people <https://onco.cc/people/du-samantha/> .